Pierre Annede1, Thomas Seisen1, Caroline Klotz2, Renaud Mazeron3, Pierre Maroun3, Claire Petit1, Eric Deutsch4, Alberto Bossi1, Christine Haie-Meder1, Cyrus Chargari5, Pierre Blanchard3. 1. Brachytherapy Unit, Gustave Roussy, Villejuif, France;; Department of Radiotherapy Department, Gustave Roussy, Villejuif, France. 2. Department of Medical Oncology, Gustave Roussy, Villejuif, France. 3. Brachytherapy Unit, Gustave Roussy, Villejuif, France;; Department of Radiotherapy Department, Gustave Roussy, Villejuif, France;; INSERM1030, Gustave Roussy Cancer Campus, Villejuif, France. 4. Department of Radiotherapy Department, Gustave Roussy, Villejuif, France;; INSERM1030, Gustave Roussy Cancer Campus, Villejuif, France;; Department of Molecular Radiotherapy, University Paris-Sud, SIRIC SOCRATES, Faculté de Médecine, Le Kremlin-Bicetre, France. 5. Brachytherapy Unit, Gustave Roussy, Villejuif, France;; Department of Radiotherapy Department, Gustave Roussy, Villejuif, France;; INSERM1030, Gustave Roussy Cancer Campus, Villejuif, France;; NRBC Department, Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France.
Abstract
BACKGROUND: Few studies with contradictory results have been published on the safety of pelvic radiation therapy (RT) in patients with inflammatory bowel disease (IBD). METHODS: From 1989 to 2015, a single center retrospective analysis was performed including all IBD patients who received pelvic external beam radiation therapy (EBRT) or brachytherapy (BT) for a pelvic malignancy. Treatment characteristics, IBD activity and gastrointestinal (GI) toxicity were examined. RESULTS: Overall, 28 patients with Crohn's disease (CD) (n=13) or ulcerative colitis (n=15) were included in the present study. Median follow-up time after irradiation was 5.9 years. Regarding IBD activity, only one and two patients experienced a severe episode within and after 6 months of follow-up, respectively. Grade 3/4 acute GI toxicity occurred in 3 (11%) patients, whereas one (3.6%) patient experienced late grade 3/4 GI toxicity. Only patients with rectal IBD location (P=0.016) or low body mass index (BMI) (P=0.012) experienced more severe IBD activity within or after 6 months following RT, respectively. CONCLUSIONS: We report an acceptable tolerance of RT in IBD patients with pelvic malignancies. Specifically, a low risk of uncontrolled flare-up was observed.
BACKGROUND: Few studies with contradictory results have been published on the safety of pelvic radiation therapy (RT) in patients with inflammatory bowel disease (IBD). METHODS: From 1989 to 2015, a single center retrospective analysis was performed including all IBD patients who received pelvic external beam radiation therapy (EBRT) or brachytherapy (BT) for a pelvic malignancy. Treatment characteristics, IBD activity and gastrointestinal (GI) toxicity were examined. RESULTS: Overall, 28 patients with Crohn's disease (CD) (n=13) or ulcerative colitis (n=15) were included in the present study. Median follow-up time after irradiation was 5.9 years. Regarding IBD activity, only one and two patients experienced a severe episode within and after 6 months of follow-up, respectively. Grade 3/4 acute GI toxicity occurred in 3 (11%) patients, whereas one (3.6%) patient experienced late grade 3/4 GI toxicity. Only patients with rectal IBD location (P=0.016) or low body mass index (BMI) (P=0.012) experienced more severe IBD activity within or after 6 months following RT, respectively. CONCLUSIONS: We report an acceptable tolerance of RT in IBD patients with pelvic malignancies. Specifically, a low risk of uncontrolled flare-up was observed.
Authors: C G Willett; C J Ooi; A L Zietman; V Menon; S Goldberg; B E Sands; D K Podolsky Journal: Int J Radiat Oncol Biol Phys Date: 2000-03-01 Impact factor: 7.038
Authors: D Y Song; W T Lawrie; R A Abrams; D R Kafonek; T M Bayless; J S Welsh; T L DeWeese Journal: Int J Radiat Oncol Biol Phys Date: 2001-10-01 Impact factor: 7.038
Authors: Renata D Peixoto; Artur R Ferreira; James M Cleary; João P Fogacci; João P Vasconcelos; Alexandre A Jácome Journal: J Gastrointest Cancer Date: 2022-03-14
Authors: Jonathan W Lischalk; Seth Blacksburg; Christopher Mendez; Michael Repka; Astrid Sanchez; Todd Carpenter; Matthew Witten; Jules E Garbus; Andrew Evans; Sean P Collins; Aaron Katz; Jonathan Haas Journal: Radiat Oncol Date: 2021-07-09 Impact factor: 3.481